An update of meta–analyses on second–generation antipsychotic drugs for schizophrenia

Stefan Leucht, Caroline Corves, Werner Kissling, John M. Davis

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

2 Scopus citations


INTRODUCTION There is continuing debate about the superiority of second-generation (“atypical”) antipsychotic drugs (SGA) compared to conventional neuroleptics (firstgeneration antipsychotic drugs, FGA) which is mainly driven by the higher cost of the former. A number of meta-analyses on this question have been published (6, 4, 1). Limitations of these meta-analyses were that most of them analyzed only overall efficacy, although SGAs are thought to be especially effective for negative symptoms and depression associated with schizophrenia. Cochrane reviews on single SGAs are available (1), but, because they were published in different reports, it is difficult to form a gestalt. The older meta-analyses also failed to thoroughly assess side effects, although these are important criteria in drug choice. Furthermore, the number of randomized controlled trials (RCT) in this area is continually increasing, which made new meta-analyses necessary. In the current chapter, we summarize the findings of three updated syatematic reviews on the effects of second-generation antipsychotics in schizophrenia (13, 14, 17), compare the results with other meta-analyses (6, 4, 1) and the results of the recent effectiveness studies, CATIE, CUtLASS, and EUFEST (19, 9, 18, 10).

Original languageEnglish
Title of host publicationSchizophrenia, Second Edition
PublisherTaylor and Francis
Number of pages10
ISBN (Electronic)9781420080063
ISBN (Print)9781420080049
StatePublished - 1 Jan 2009
Externally publishedYes


Dive into the research topics of 'An update of meta–analyses on second–generation antipsychotic drugs for schizophrenia'. Together they form a unique fingerprint.

Cite this